What is HC Wainwright's Forecast for CRVS Q3 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Monday, August 11th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.15). The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.50) EPS and FY2027 earnings at ($0.40) EPS.

Several other equities research analysts also recently issued reports on the company. Mizuho set a $11.00 price objective on Corvus Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, May 20th. Oppenheimer reaffirmed an "outperform" rating and set a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. Finally, Wall Street Zen raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Corvus Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $15.00.

View Our Latest Research Report on CRVS

Corvus Pharmaceuticals Trading Up 11.1%

Shares of Corvus Pharmaceuticals stock opened at $5.00 on Thursday. The stock has a 50-day moving average price of $4.21 and a 200 day moving average price of $4.05. The company has a market cap of $372.55 million, a P/E ratio of -4.95 and a beta of 0.42. Corvus Pharmaceuticals has a 1 year low of $2.54 and a 1 year high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03.

Insider Buying and Selling at Corvus Pharmaceuticals

In other news, Director Peter A. Thompson sold 1,176,332 shares of the firm's stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $4.16, for a total transaction of $4,893,541.12. Following the completion of the sale, the director directly owned 7,165,006 shares of the company's stock, valued at $29,806,424.96. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 28.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CRVS. Sowell Financial Services LLC acquired a new position in shares of Corvus Pharmaceuticals during the 1st quarter valued at about $38,000. Virtus ETF Advisers LLC acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter valued at about $47,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $49,000. ProShare Advisors LLC acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $54,000. Finally, Alpine Global Management LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $62,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.

Further Reading

• Five stocks we like better than Corvus Pharmaceuticals
• TSX Venture Exchange (Formerly Canadian Venture Exchange)
• Data Centers Create a Bull Case for These Nuclear 3 Stocks
• Manufacturing Stocks Investing
• Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock
• Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
• 3 Companies That Will Profit From Trump's Semiconductor Tariffs

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?

Before you consider Corvus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.

While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here